论文部分内容阅读
目的探讨自体CIK细胞对晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)维持治疗的临床效果。方法对16例晚期NSCLC患者在手术、放疗、化疗获益基础上,采用自体CIK进行维持治疗。结果患者使用自体CIK细胞治疗后,短期内生存质量有所提高,未发现严重毒副作用。结论自体CIK细胞治疗晚期非小细胞肺癌有控制肿瘤、增强患者免疫功能、改善生存质量(Quality of Life,QOL)以及延长生存期的趋势。
Objective To investigate the clinical effect of autologous CIK cells in the maintenance of advanced non-small cell lung cancer (NSCLC). Methods Sixteen patients with advanced NSCLC were treated with autologous CIK on the basis of the benefit of surgery, radiotherapy and chemotherapy. Results After treated with autologous CIK cells, the quality of life improved in short term and no serious side effects were found. Conclusions Autologous CIK cells can be used to treat advanced non-small cell lung cancer (NSCLC) in the treatment of tumor, enhancing immune function, improving quality of life (QOL) and prolonging survival.